Search Results - Thomas Powles

Refine Results
  1. 1
    Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer

    Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer by Thomas Powles

    Published 2020
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  2. 2
    Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic

    Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic by Silke Gillessen, Thomas Powles

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now

    A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now by J Bellmunt, Thomas Powles, Nicholas J. Vogelzang

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma

    The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma by Thomas Powles, Jill Walker, J. Andrew Williams, Joaquim Bellmunt

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    The cancer-immunity cycle: Indication, genotype, and immunotype

    The cancer-immunity cycle: Indication, genotype, and immunotype by Ira Mellman, Daniel S. Chen, Thomas Powles, Shannon J. Turley

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial

    Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial by Darren R. Feldman, Robert Huddart, Emma Hall, J. Beyer, Thomas Powles

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

    Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma by Robert J. Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold, Toni K. Choueiri

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Rise of Antibody-Drug Conjugates: The Present and Future

    Rise of Antibody-Drug Conjugates: The Present and Future by Mythili Shastry, Avantika Gupta, Sarat Chandarlapaty, Matthew R. Young, Thomas Powles, Erika Hamilton

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis

    The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis by Thomas Powles, David Robinson, Jonathan Shamash, Henrik Møller, N. L. Tranter, R.T.D. Oliver

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches

    Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches by Dongkui Song, Thomas Powles, Lei Shi, Lirong Zhang, Molly A. Ingersoll, Yong‐Jie Lu

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events by Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albigès, Rachel H. Giles, Eric Jonasch

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection

    Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection by Thomas Powles, David Robinson, Justin Stebbing, Jonathan Shamash, Mark Nelson, Brian Gazzard, Sundhiya Mandelia, Henrik Møller, Mark Bower

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib

    Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib by Jonathan Welti, Morgane Gourlaouen, Thomas Powles, Sakunthala C. Kudahetti, Paul A. Wilson, Daniel M. Berney, Andrew R. Reynolds

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer

    The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer by Nick van Dijk, Samuel A. Funt, Christian U. Blank, Thomas Powles, Jonathan E. Rosenberg, Michiel S. van der Heijden

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  15. 15
    Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway

    Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway by Thomas Powles, Robert te Poele, Jonathan Shamash, Tracy Chaplin, David Propper, Simon Joel, R.T.D. Oliver, Wai M. Liu

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma by Thomas Powles, Laurence Albigès, Axel Bex, Viktor Grünwald, Camillo Porta, Giuseppe Procopio, Manuela Schmidinger, Cristina Suárez, Guillermo de Velasco

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Local treatments for metastases of renal cell carcinoma: a systematic review

    Local treatments for metastases of renal cell carcinoma: a systematic review by Saeed Dabestani, Lorenzo Marconi, Fabian Hofmann, Fiona Stewart, Thomas Lam, Steven Canfield, Michael Staehler, Thomas Powles, Börje Ljungberg, Axel Bex

    Published 2014
    Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    Hypothalamo-Pituitary Abnormalities in Adult Patients with Langerhans Cell Histiocytosis: Clinical, Endocrinological, and Radiological Features and Response to Treatment

    Hypothalamo-Pituitary Abnormalities in Adult Patients with Langerhans Cell Histiocytosis: Clinical, Endocrinological, and Radiological Features and Response to Treatment by Gregory Kaltsas, Thomas Powles, Jane Evanson, P N Plowman, J. E. Drinkwater, P Jenkins, JP Monson, G. M. Besser, Ashley Grossman

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients

    Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients by Thomas Powles, Sergio Bracarda, Chen Mei, Elliot Norry, Natalie Compton, Mark Heise, Thomas E. Hutson, Philipp Harter, Christopher L. Carpenter, Lini Pandite, Neil Kaplowitz

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  20. 20
    Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma

    Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma by Jennifer L. Beaumont, John M. Salsman, Jose Diaz, Keith C. Deen, Lauren McCann, Thomas Powles, Michelle D. Hackshaw, Robert J. Motzer, David Cella

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: